(Q43252634)

English

Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma

scientific article published in November 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1

object named as

E Bien

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

author name string

A Balcerska

2

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

publication date

1 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Scandinavian Journal of Immunology

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

490-500

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2009.02313.X

21 January 2018

Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2009.02313.X

21 January 2018

Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2009.02313.X

21 January 2018

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2009.02313.X

21 January 2018

Prognostic factors in Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2009.02313.X

21 January 2018

Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2009.02313.X

21 January 2018

Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2009.02313.X

21 January 2018

Identifiers

10.1111/J.1365-3083.2009.02313.X

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43252634&oldid=2211178437"